Sorcero has secured $42.5 million in Series B financing led by NewSpring Growth, with participation from Leawood Venture Capital and Blu Ventures, bringing the company’s total capital raised to $59 million. The new funding will support rapid expansion across medical affairs, safety, scientific communications, and medical device markets, while scaling its AI platform designed to help life sciences organizations drive adoption of advanced therapies.
The Washington-based company has already established a significant footprint in the pharmaceutical sector, with one-third of the top 30 global pharma companies using its platform to extract insights from medical data and support evidence-based engagement with healthcare professionals. Sorcero reports that customers are improving productivity in scientific evidence generation by up to 92%, accelerating insight creation by up to 72%, and shortening publication timelines by up to 5 months.
The Sorcero Intelligence Platform brings together medically tuned AI, the industry’s most extensive medically enriched data corpus, and an architecture designed to meet regulatory and privacy requirements. Its solutions include Sorcero Medical, Sorcero SciComms, Sorcero Safety, and Sorcero Medtech. The platform aims to advance physician-targeted communication models by enabling precise, evidence-driven engagement that reflects therapeutic complexity and real-world patient needs.
Sorcero’s approach arrives at a critical moment. Precision medicine and specialty drugs now represent the overwhelming majority of new product approvals. Yet even with billions spent on research and development, many advanced therapies experience slow adoption and limited payor coverage. The number of Phase III drugs exceeds 1,300, while more than three-quarters of new products achieve less than 50% coverage after 6 months. Meanwhile, many healthcare professionals report feeling inundated by irrelevant promotional content and underserved by traditional outreach methods.
The company’s platform aggregates hundreds of data sources and synthesizes real-world evidence to build comprehensive profiles of more than 40 million healthcare professionals and 100 million scientific contributors worldwide. Its AI agents process vast medical datasets, including 263 million publications and 1.3 billion citations, along with congress materials, reports, CRM interactions, safety cases, and medical inquiries. The system delivers clinical inclusion accuracy of 96.1 percent, exceeding regulatory thresholds and matching PhD-level expert performance.
This data-driven approach positions Sorcero to meet the growing market need for precision targeting, clarity in evidence, and continuous monitoring of efficacy and safety signals. The platform enables life sciences companies to identify which physicians and researchers are most active in relevant domains and to deliver timely and tailored scientific information. It also strengthens the ability to identify patients who may benefit from specific treatments and provides ongoing insights that support therapy adoption in real-world settings.
Investor interest reflects the growing demand for specialized AI platforms that meet the stringent requirements of the healthcare sector. Sorcero is supported by partnerships with Google Cloud, Springer Nature, ServiceNow, USDM Life Sciences, and Snowflake. The company’s recent acquisition of Axiom Health expands its capabilities and reach in the medical device industry. Sorcero’s solutions are available directly, through the NIH STRIDES program, on Google Cloud Marketplace, and on additional digital platforms.
Founded in 2018, Sorcero has received numerous awards for its innovation in medical AI and continues to expand its global presence as life sciences organizations accelerate their shift toward evidence-driven engagement models.
KEY QUOTES
“Our vision is to create a unified intelligence platform for the precision medicine era. We’re pioneering a new evidence-based medical affairs model where science, personalized for physicians, drives engagement and product adoption. This puts doctors’ evidence needs at the center and helps life sciences generate real-world insights radically faster, identify patients in need of specific treatments, and continually improve patient outcomes to drive healthcare provider adoption.”
Dipanwita Das, CEO and Co-Founder, Sorcero
“We see tremendous potential in AI helping pharma engage the right doctors with the right evidence at the right time and ultimately serve patients who can’t wait months for critical information on life-changing therapies. Sorcero is uniquely positioned to become the vertical AI platform precision medicine demands and provide the medical insights that get treatments to patients faster.”
Hart Callahan, General Partner, NewSpring
“We invested in Sorcero because their time-to-replicate advantage and expanding data network create a widening moat as they scale. As specialty therapeutics become the norm, life sciences organizations must be data-driven and science-focused to improve therapy adoption. There’s a lot of hype around AI, but few companies deliver measurable value at scale. Sorcero stands out as a proven AI platform—driving real outcomes, accelerating evidence generation, and transforming how therapies reach patients.”
Dan Goldsmith, Life Sciences Software Veteran and Investor
